Stifel raised the firm’s price target on Elanco (ELAN) to $27 from $23 and keeps a Buy rating on the shares. Elanco’s stock currently trades at a premium to Zoetis (ZTS), but it is now expected to grow faster in 2025 relative to the market leader, the analyst tells investors. “More importantly,” Elanco’s margins are half of Zoetis’ and the margin expansion opportunity is “significant” over the next 12-24 months, which should allow for EBITDA growth to outstrip Zoetis, the analyst added in a post-Q3 note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco Animal Health: Strong U.S. Performance and Innovative Portfolio Drive Buy Rating
- Elanco raises FY25 adjusted EPS view to 91c-94c, consensus 91c
- Elanco sees Q4 adjusted EPS 9c-12c, consensus 14c
- Elanco reports Q3 EPS 19c, consensus 13c
- Elanco Animal Health Amends Credit Agreement for Refinancing